<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /home/lopez/grobid/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Long-term immunogenicity of the influenza vaccine at reduced intradermal and full intramuscular doses among healthy young adults</title>
			</titleStmt>
			<publicationStmt>
				<publisher>Korean Vaccine Society (KAMJE)</publisher>
				<availability status="unknown"><p>Copyright Korean Vaccine Society (KAMJE)</p>
				</availability>
				<date type="published" when="2013">2013</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Joon</forename><forename type="middle">Young</forename><surname>Song</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Infectious Diseases</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">Asian Pacific Influenza Institute</orgName>
								<orgName type="institution" key="instit2">Korea University College of Medicine</orgName>
								<address>
									<settlement>Seoul</settlement>
									<country key="KR">Korea</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>MD</roleName><forename type="first">Hee</forename><forename type="middle">Jin</forename><surname>Cheong</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Infectious Diseases</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">Asian Pacific Influenza Institute</orgName>
								<orgName type="institution" key="instit2">Korea University College of Medicine</orgName>
								<address>
									<settlement>Seoul</settlement>
									<country key="KR">Korea</country>
								</address>
							</affiliation>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Infectious Diseases</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ji</forename><forename type="middle">Yun</forename><surname>Noh</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Infectious Diseases</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">Asian Pacific Influenza Institute</orgName>
								<orgName type="institution" key="instit2">Korea University College of Medicine</orgName>
								<address>
									<settlement>Seoul</settlement>
									<country key="KR">Korea</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tae</forename><forename type="middle">Un</forename><surname>Yang</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Infectious Diseases</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yu</forename><forename type="middle">Bin</forename><surname>Seo</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Infectious Diseases</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kyung-Wook</forename><surname>Hong</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Infectious Diseases</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">In</forename><forename type="middle">Seon</forename><surname>Kim</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Infectious Diseases</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Won</forename><forename type="middle">Suk</forename><surname>Choi</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Infectious Diseases</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Woo</forename><forename type="middle">Joo</forename><surname>Kim</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">Asian Pacific Influenza Institute</orgName>
								<orgName type="institution" key="instit2">Korea University College of Medicine</orgName>
								<address>
									<settlement>Seoul</settlement>
									<country key="KR">Korea</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="department">Division of Infectious Disease, Department of Internal Medicine</orgName>
								<orgName type="institution">Korea University Guro Hospital</orgName>
								<address>
									<addrLine>148 Gurodong-ro, Guro-gu</addrLine>
									<postCode>152-703</postCode>
									<settlement>Seoul</settlement>
									<country key="KR">Korea</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Long-term immunogenicity of the influenza vaccine at reduced intradermal and full intramuscular doses among healthy young adults</title>
					</analytic>
					<monogr>
						<title level="j" type="main">Clinical and Experimental Vaccine Research</title>
						<title level="j" type="abbrev">Clin Exp Vaccine Res</title>
						<idno type="ISSN">2287-3651</idno>
						<idno type="eISSN">2287-366X</idno>
						<imprint>
							<publisher>Korean Vaccine Society (KAMJE)</publisher>
							<biblScope unit="volume">2</biblScope>
							<biblScope unit="issue">2</biblScope>
							<biblScope unit="page">115</biblScope>
							<date type="published" when="2013" />
						</imprint>
					</monogr>
					<idno type="DOI">10.7774/cevr.2013.2.2.115</idno>
					<idno type="PMID">23858402</idno>
					<idno type="PMCID">PMC3710919</idno>
					<ptr type="open-access" target="http://synapse.koreamed.org/Synapse/Data/PDFData/0209CEVR/cevr-2-115.pdf" />
					<note type="submission">Received: March 21, 2013 Revised: March 31, 2013 Accepted: April 10, 2013</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.6.2-SNAPSHOT" ident="GROBID" when="2020-08-13T21:25+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Vaccines</term>
					<term>Influenza vaccines</term>
					<term>Immunogenicity</term>
					<term>Intradermal injections</term>
					<term>Adult</term>
				</keywords>
			</textClass>
			<abstract>
				<p>To prepare for vaccine shortages under an influenza pandemic, several antigensparing strategies have been investigated. This study was aimed to evaluate the immunogenicity of influenza vaccine at reduced intradermal and full intramuscular dose. Materials and Methods: We compared the effect of one-fifth and one-half intradermal doses to the full intramuscular dose on immunogenicity in healthy young adults, using a commercial influenza vaccine. A hemagglutination inhibition assay was used to compare the immunogenicity of the vaccination methods. Results: The one-fifth intradermal dose (3 µg hemagglutinin antigen, HA) was given to 30 participants, the one-half intradermal dose (7.5 µg HA) was given to 30, and the full intramuscular dose (15 µg HA) was given to 32. No significant differences among injection routes and dosages were seen for seroprotection rate, seroconversion rate, or geometric mean titer (GMT) fold-increase for A/H1N1, A/H3N2, and B at around 4 weeks from vaccination. Although GMT for influenza B was significantly lower at six months for the one-fifth intradermal vaccination compared to the full-dose intramuscular vaccination (32.8 vs. 63.2, p=0.048), all three groups met the Evaluation of Medicinal Products (EMA) immunogenicity criteria through 1 to 6 months. Conclusion: Intradermal administration of a one-fifth dose of influenza vaccine elicited antibody responses comparable to the intradermal one-half dose and a conventional intramuscular vaccination at 1 month post-vaccination. The immunogenicity of the one-fifth intradermal dose was sufficient to meet the requirement for the EMA criteria at six months after influenza vaccination.</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>Influenza is one of the most common infectious diseases, with global epidemics occurring every 10-40 years. Although relatively benign, influenza can be associated with significant morbidity and mortality; influenza-related complications include pneumonia, encephalitis, myocarditis, and gradual deterioration of organ functions. Annual vaccination is the primary measure for preventing influenza-related morbidity and mortality, but the vaccine supply can be limited in an early pandemic situation. To prepare for potential vaccine shortages under an influenza pandemic, several antigensparing strategies have been investigated. These include adjuvanted vaccines and new Intradermal influenza vaccination requires less antigen to be as effective as regular intramuscular vaccination. The improved immune response is due to the higher level of dendritic cells in the dermis than in the muscle <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref>. Furthermore, the dermis has a rich supply of blood and lymphatic vessels that aids circulation of immune cells <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b4">5]</ref>.</p><p>In this study, we compared the long-term immunogenicity of intradermal vaccination at one-fifth and one-half doses to full-dose intramuscular vaccination of a commercial influenza vaccine in healthy young adults.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Vaccine and study design</head><p>During the 2006-2007 influenza season, we compared the long-term immunogenicity in healthy young adults of an intradermal influenza vaccination at one-fifth and one-half the conventional antigenic contents with an intramuscular vaccination at the conventional dose ( <ref type="figure">Fig. 1)</ref>. We randomly assigned 96 participants in a 1:1:1 ratio to three vaccination groups: intradermal one-fifth dose (0.1 mL, 3 µg hemagglutinin antigen [HA]/strain), intradermal one-half (0.25 mL, 7.5 µg HA/strain), and intramuscular full-dose (0.5 mL, 15 µg HA/strain). Serum hemagglutinin inhibition (HI) antibody titers were determined for recommended influenza strains pre-vaccination and at one and six months after vaccination.</p><p>The trivalent inactivated split vaccine (Influenza HA vaccine, Green Cross, Yongin, Korea), containing 15 µg HA/strain per 0.5 mL dose, was used. The vaccine contained the following influenza strains: A/New Caledonia/20/99 (H1N1)-like virus, A/Wisconsin/67/2005 (H3N2)-like virus, and B/Malaysia/2506/2004-like virus.</p><p>Subjects enrolled in the study were healthy young adults aged 18-30 years. Exclusion criteria included immunosuppressant use, hypersensitivity to any vaccine component (including eggs), or a history of Guillain-Barre syndrome. Other exclusion criteria included thrombocytopenia, any coagulation disorder contraindicating intramuscular injection, or current febrile illness or another acute illness. Anyone who received gamma globulin during the previous three months or any other vaccination within the past 30 days was excluded.</p><p>The study was approved by the ethics committee of Korea University Guro Hospital (IRB No. KUGH0691) and was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. All participants provided written, informed consent before enrollment. Venous blood samples of 10 mL were taken on day 0, post-vaccination day 30±7, and post-vaccination day 180±7.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>HI assay</head><p>Standard microtiter HI assays was performed as previously described <ref type="bibr" target="#b5">[6]</ref>. A titer of ≥1:40 was considered a protective level <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b7">8]</ref>. Geometric mean titer (GMT) was determined prevaccination and at 1 month and 6 months post-vaccination. Serologic response, measured by HI antibody titer, was assessed using the criteria of the Evaluation of Medicinal Products (EMA) <ref type="bibr" target="#b8">[9]</ref>. To confirm protective immunogenicity, at least one of the following three criteria were required for each influenza virus strain: 1) GMT-fold increase &gt;2.5-fold, 2) Seroprotection rate &gt;70%, and 3) Seroconversion rate &gt;40%.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p>All statistical analysis was by SPSS version 15.0 (SPSS Inc., Chicago, IL, USA). Descriptive statistics are reported as number of participants and corresponding percentage. HI antibody titers are expressed as geometric mean with 95% confidence interval. Analysis of variance (ANOVA) was used to assess variation of GMTs among groups for each time point; multiple comparison tests were based on Turkey's method. Categorical variables were analyzed using chi-square test (Fisher's exact test for less than 30 samples). Statistical significance was signified by a p-value less than 0.05. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p>Among 96 enrolled participants, 4 were dropped from the study because of declining serum sampling. The experimental groups were comprised of 30, 30, and 32 participants in the intradermal one-fifth dose (0.1 mL, 3 µg HA), intradermal one-half dose (0.25 mL, 7.5 µg HA), and intramuscular full-dose (0.5 mL, 15 µg HA) groups, respectively. Baseline demographic characteristics of patients are in <ref type="table" target="#tab_1">Table 1</ref>. No remarkable differences were observed between the groups. All three groups met the EMA immunogenicity criteria in the 1-6 month study period <ref type="table" target="#tab_2">(Table 2)</ref>. For influenza A/H1N1 virus, the seroprotection (titer≥1:40) rates for the groups were 80.0% for the one-fifth dose, 90.0% for the one-half dose, and  87.5% for the full dose. For A/H3N2 virus, rates were 70.0% for the one-fifth dose, 90.0% for the one-half dose, and 84.4% for the full dose. For influenza B virus, rates were 60.0%, 60.0%, and 71.9%. No significant intergroup differences were observed at 1 month or 6 months post-vaccination <ref type="table" target="#tab_2">(Table 2)</ref>. GMTs increased by &gt;2.5 in the 1-6 months for all 3 strains irrespective of injection route or dosage <ref type="figure" target="#fig_1">(Fig. 2)</ref>. Seroconversion rates were above 40% for all three strains at 1 month post-vaccination, but the rate for influenza B declined to less than 40% at 6 months for the one-fifth dose vaccination <ref type="table" target="#tab_2">(Table 2)</ref>. GMT for influenza B was significantly lower at 6 months after the one-fifth intradermal dose compared to the full-dose intramuscular vaccination: 32.8 vs. 63.2 (p=0.048) ( <ref type="table" target="#tab_2">Table 2)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p>This study showed that the immunogenicity of one-fifth and one-half doses of intradermal seasonal influenza vaccine were largely comparable to full-dose intramuscular vaccination in healthy young adults. All three groups satisfied the EMA immunogenicity criteria for influenza vaccines, although the intradermal one-fifth dose vaccination elicited lower antibody responses than the intradermal one-half dose and the conventional dose of an intramuscular vaccination. Intramuscular vaccination bypasses the skin's immune system, while intradermal vaccination targets dense populations of dendritic cells in the skin. Skin is considered a desirable target for vaccination; about 25% of the skin is covered by dendritic cells, which are postulated to acquire antigens in peripheral tissue by priming naive T cells <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref>. Moreover, antigen is suggested to become trapped in the cutaneous tissue for long periods after intradermal injection, compared to in-tramuscular injection <ref type="bibr" target="#b9">[10]</ref>. Several trials of intradermal influenza vaccines have studied the characteristic features of the dermal immune system in adults of diverse ages <ref type="bibr" target="#b10">[11,</ref><ref type="bibr" target="#b11">12]</ref>. A recent literature review <ref type="bibr" target="#b10">[11]</ref> found 10 trials using reduced-dose intradermal influenza vaccines ranging from 3 to 9 µg HA per strain. Among these trials, five used a 3-µg dose <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref>. Of the 10 trials, 8 found comparable responses between intradermal influenza vaccines at a reduced dose and a full-dose intramuscular vaccine <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref>. One trial showed that a dose-sparing intradermal vaccine was superior to a conventional-dose intramuscular vaccine <ref type="bibr" target="#b20">[21]</ref>. Thus, intradermal influenza vaccines at a reduced dose can be immunogenic in a way that is comparable to a full-dose intramuscular vaccine. However, data on antibody persistence has been insufficient. In this study, we showed that even a one-fifth dose of an intradermal vaccine induced antibody responses that persisted for six months.</p><p>This study has some limitations. First, we did not include elderly people, so long-term immunogenicity needs to be investigated among this population. Second, cross-reactive immunogenicity against drifted strains was not evaluated. Third, the history of influenza infections in the previous year was not considered.</p><p>Recently, the United States expanded the recommendation of influenza vaccination to children and adults without high-risk conditions <ref type="bibr" target="#b21">[22]</ref>. In addition to these increased requirements, we experienced vaccine shortages during the 2009 influenza pandemic, and the United States suffered from vaccine shortages from the contamination of a vaccineproducing plant during the 2004-2005 season <ref type="bibr" target="#b22">[23]</ref>. Thus, dosesparing intradermal vaccines might be an effective strategy for preparation for an influenza pandemic, and could also be  </p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Long-term immunogenicity</head><label></label><figDesc>of the influenza vaccine at reduced intradermal and full intramuscular doses among healthy young adults http://www.ecevr.org/ http://dx.doi.org/10.7774/cevr.2013.2.2.115 methods of administering vaccines such as intradermal and subcutaneous injection.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2 .</head><label>2</label><figDesc>Geometric mean titer (GMT) fold-increases were assessed at 1 month post-vaccination (A) and 6 months post-vaccination (B), by hemagglutination inhibition assay.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1 .</head><label>1</label><figDesc>Baseline characteristics of study subjects</figDesc><table><row><cell>Characteristic</cell><cell>One-fifth dose, intradermal (n = 30)</cell><cell>One-half dose, intradermal (n = 30)</cell><cell>Full-dose, intramuscular (n = 32)</cell><cell>p-value</cell></row><row><cell>Age (yr)</cell><cell>24.7± 1.6</cell><cell>25.3± 2.1</cell><cell>25.3± 2.3</cell><cell>0.431</cell></row><row><cell>Male (%)</cell><cell>17 (56.7)</cell><cell>18 (60.0)</cell><cell>22 (68.8)</cell><cell>0.597</cell></row><row><cell>Influenza vaccination in the previous year (%)</cell><cell>6 (20.0)</cell><cell>6 (20.0)</cell><cell>6 (18.8)</cell><cell>0.990</cell></row><row><cell>BMI (kg/m 2 )</cell><cell>20.9± 2.3</cell><cell>21.7± 2.9</cell><cell>21.9± 3.2</cell><cell>0.301</cell></row></table><note>Values are presented as mean± SD or n (%). SD, standard deviation; BMI, body mass index.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2 .</head><label>2</label><figDesc>Comparison of short-and long-term immune responses after influenza vaccination, by hemagglutination inhibition assay</figDesc><table><row><cell>Subtype</cell><cell>Parameters of immunogenicity</cell><cell>One-fifth dose, intradermal (n = 30)</cell><cell>One-half dose, intradermal (n = 30)</cell><cell>Full dose, intramuscular (n = 32)</cell><cell>p-value</cell></row><row><cell cols="2">Influenza A/H1N1 Sero-protection rate (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>1 mo post-vaccination</cell><cell>80.0 (62.5-90.4)</cell><cell>90.0 (74.2-96.4)</cell><cell>87.5 (71.8-94.9)</cell><cell>0.511</cell></row><row><cell></cell><cell>6 mo post-vaccination</cell><cell>76.7 (58.9-88.1)</cell><cell>90.0 (74.2-96.4)</cell><cell>87.5 (71.8-94.9)</cell><cell>0.309</cell></row><row><cell></cell><cell>Sero-conversion rate (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>1 mo post-vaccination</cell><cell>43.3 (27.3-60.9)</cell><cell>40.0 (24.5-57.8)</cell><cell>46.9 (30.8-63.6)</cell><cell>0.861</cell></row><row><cell></cell><cell>6 mo post-vaccination</cell><cell>36.7 (21.9-54.6)</cell><cell>40.0 (24.5-57.8)</cell><cell>43.8 (28.1-60.8)</cell><cell>0.850</cell></row><row><cell></cell><cell>Geometric mean titer</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Pre-vaccination</cell><cell>26.0 (17.5-38.5)</cell><cell>35.9 (24.6-52.4)</cell><cell>33.0 (20.7-52.5)</cell><cell>0.513</cell></row><row><cell></cell><cell>1 mo post-vaccination</cell><cell>106.3 (65.5-172.7)</cell><cell>150.5 (99.7-227.2)</cell><cell>129.2 (87.1-191.4)</cell><cell>0.515</cell></row><row><cell></cell><cell>6 mo post-vaccination</cell><cell>97.3 (59.7-158.5)</cell><cell>119.5 (78.8-181.1)</cell><cell>115.9 (77.9-172.4)</cell><cell>0.764</cell></row><row><cell cols="2">Influenza A/H3N2 Sero-protection rate (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>1 mo post-vaccination</cell><cell>70.0 (52.0-83.3)</cell><cell>90.0 (74.2-96.4)</cell><cell>84.4 (68.1-93.0)</cell><cell>0.120</cell></row><row><cell></cell><cell>6 mo post-vaccination</cell><cell>70.0 (52.0-83.3)</cell><cell>90.0 (74.2-96.4)</cell><cell>84.4 (68.1-93.0)</cell><cell>0.120</cell></row><row><cell></cell><cell>Sero-conversion rate (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>1 mo post-vaccination</cell><cell>43.3 (27.3-60.9)</cell><cell>50.0 (33.1-66.9)</cell><cell>56.3 (39.2-71.9)</cell><cell>0.597</cell></row><row><cell></cell><cell>6 mo post-vaccination</cell><cell>43.3 (27.3-60.9)</cell><cell>43.3 (27.3-60.9)</cell><cell>56.3 (39.2-71.9)</cell><cell>0.498</cell></row><row><cell></cell><cell>Geometric mean titer</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Pre-vaccination</cell><cell>20.8 (15.8-27.3)</cell><cell>26.0 (18.6-36.3)</cell><cell>25.4 (18.4-35.3)</cell><cell>0.525</cell></row><row><cell></cell><cell>1 mo post-vaccination</cell><cell>74.4 (48.6-113.7)</cell><cell>92.7 (65.9-130.2)</cell><cell>95.4 (66.7-136.4)</cell><cell>0.581</cell></row><row><cell></cell><cell>6 mo post-vaccination</cell><cell>66.5 (44.7-98.9)</cell><cell>92.7 (65.0-131.9)</cell><cell>101.7 (68.9-150.1)</cell><cell>0.241</cell></row><row><cell>Influenza B</cell><cell>Sero-protection rate (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>1 mo post-vaccination</cell><cell>60.0 (42.2-75.5)</cell><cell>60.0 (42.2-75.5)</cell><cell>71.9 (54.5-84.4)</cell><cell>0.527</cell></row><row><cell></cell><cell>6 mo post-vaccination</cell><cell>60.0 (42.2-75.5)</cell><cell>60.0 (42.2-75.5)</cell><cell>68.8 (52.3-82.0)</cell><cell>0.710</cell></row><row><cell></cell><cell>Sero-conversion rate (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>1 mo post-vaccination</cell><cell>40.0 (24.5-57.8)</cell><cell>40.0 (24.5-57.8)</cell><cell>46.9 (30.8-63.6)</cell><cell>0.817</cell></row><row><cell></cell><cell>6 mo post-vaccination</cell><cell>26.7 (14.2-44.6)</cell><cell>40.0 (24.5-57.8)</cell><cell>46.9 (30.8-63.6)</cell><cell>0.252</cell></row><row><cell></cell><cell>Geometric mean titer</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Pre-vaccination</cell><cell>12.7 (9.9-16.3)</cell><cell>13.0 (9.9-17.0)</cell><cell>13.3 (10.3-17.1)</cell><cell>0.969</cell></row><row><cell></cell><cell>1 mo post-vaccination</cell><cell>42.3 (29.5-60.6)</cell><cell>55.6 (39.2-78.9)</cell><cell>71.9 (49.2-105.3)</cell><cell>0.114</cell></row><row><cell></cell><cell>6 mo post-vaccination</cell><cell>32.8 (22.7-47.4) a</cell><cell>54.4 (38.2-77.4) a,b</cell><cell>63.2 (40.3-99.1) b</cell><cell>0.048</cell></row></table><note>The same letters indicate non-significant differences between groups based on Tukey's multiple comparison tests. The numbers in parentheses represent 95% confidence interval. http://www.ecevr.org/http://dx.doi.org/10.7774/cevr.2013.2.2.115</note></figure>
		</body>
		<back>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Epidermal Langerhans cells: from neurons to nature&apos;s adjuvants</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Jakob</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">C</forename><surname>Udey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Adv Dermatol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="209" to="58" />
			<date type="published" when="1999" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Dose Sparing with Intradermal Injection of Influenza Vaccine</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Richard</forename><forename type="middle">T</forename><surname>Kenney</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sarah</forename><forename type="middle">A</forename><surname>Frech</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Larry</forename><forename type="middle">R</forename><surname>Muenz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christina</forename><forename type="middle">P</forename><surname>Villar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gregory</forename><forename type="middle">M</forename><surname>Glenn</surname></persName>
		</author>
		<idno type="DOI">10.1056/nejmoa043540</idno>
		<idno type="PMID">15525714</idno>
	</analytic>
	<monogr>
		<title level="j">New England Journal of Medicine</title>
		<title level="j" type="abbrev">N Engl J Med</title>
		<idno type="ISSN">0028-4793</idno>
		<idno type="ISSNe">1533-4406</idno>
		<imprint>
			<biblScope unit="volume">351</biblScope>
			<biblScope unit="issue">22</biblScope>
			<biblScope unit="page" from="2295" to="2301" />
			<date type="published" when="2004-11-25" />
			<publisher>New England Journal of Medicine (NEJM/MMS)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Intradermal Influenza Vaccination — Can Less Be More?</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">John</forename><forename type="middle">R</forename><surname>La Montagne</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anthony</forename><forename type="middle">S</forename><surname>Fauci</surname></persName>
		</author>
		<idno type="DOI">10.1056/nejme048314</idno>
		<idno type="PMID">15525715</idno>
	</analytic>
	<monogr>
		<title level="j">New England Journal of Medicine</title>
		<title level="j" type="abbrev">N Engl J Med</title>
		<idno type="ISSN">0028-4793</idno>
		<idno type="ISSNe">1533-4406</idno>
		<imprint>
			<biblScope unit="volume">351</biblScope>
			<biblScope unit="issue">22</biblScope>
			<biblScope unit="page" from="2330" to="2332" />
			<date type="published" when="2004-11-25" />
			<publisher>New England Journal of Medicine (NEJM/MMS)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Intradermal vaccine delivery: Will new delivery systems transform vaccine administration?</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paul</forename><forename type="middle">Henri</forename><surname>Lambert</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Philippe</forename><forename type="middle">E</forename><surname>Laurent</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.vaccine.2008.03.095</idno>
		<idno type="PMID">18486285</idno>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<title level="j" type="abbrev">Vaccine</title>
		<idno type="ISSN">0264-410X</idno>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">26</biblScope>
			<biblScope unit="page" from="3197" to="3208" />
			<date type="published" when="2008-06" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jean-François</forename><surname>Nicolas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bruno</forename><surname>Guy</surname></persName>
		</author>
		<idno type="DOI">10.1586/14760584.7.8.1201</idno>
		<idno type="PMID">18844594</idno>
	</analytic>
	<monogr>
		<title level="j">Expert Review of Vaccines</title>
		<title level="j" type="abbrev">Expert Review of Vaccines</title>
		<idno type="ISSN">1476-0584</idno>
		<idno type="ISSNe">1744-8395</idno>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1201" to="1214" />
			<date type="published" when="2008-10" />
			<publisher>Informa UK Limited</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Humoral and cellular immune responses to influenza vaccine in patients with advanced cirrhosis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hee-Jin</forename><surname>Cheong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Joon-Young</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jeong-Won</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jong-Eun</forename><surname>Yeon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kwan-Soo</forename><surname>Byun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chang-Hong</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hyun-Il</forename><surname>Cho</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tai-Gyu</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Woo-Joo</forename><surname>Kim</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.vaccine.2005.11.064</idno>
		<idno type="PMID">16406176</idno>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<title level="j" type="abbrev">Vaccine</title>
		<idno type="ISSN">0264-410X</idno>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">13</biblScope>
			<biblScope unit="page" from="2417" to="2422" />
			<date type="published" when="2006-03" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Hobson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">L</forename><surname>Curry</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">S</forename><surname>Beare</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Ward-Gardner</surname></persName>
		</author>
		<idno type="DOI">10.1017/s0022172400022610</idno>
		<idno type="PMID">4509641</idno>
		<idno type="PMCID">PMC2130285</idno>
		<idno type="PII">S0022172400022610</idno>
		<idno type="ark">ark:/67375/6GQ-170M0NLB-Z</idno>
		<idno type="istexId">D3A202069BB7A706BFC3A09670022BE05AF8AF8D</idno>
		<ptr type="open-access" target="https://www.cambridge.org/core/services/aop-cambridge-core/content/view/BE4AB655EE41499C5C25349AEDD22C20/S0022172400022610a.pdf/div-class-title-the-role-of-serum-haemagglutination-inhibiting-antibody-in-protection-against-challenge-infection-with-influenza-a2-and-b-viruses-div.pdf" />
	</analytic>
	<monogr>
		<title level="j">Journal of Hygiene</title>
		<title level="j" type="abbrev">J. Hyg.</title>
		<idno type="ISSN">0022-1724</idno>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="issue">04</biblScope>
			<biblScope unit="page" from="767" to="777" />
			<date type="published" when="1972-12" />
			<publisher>Cambridge University Press (CUP)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Natural or vaccine-induced antibody as a predictor of immunity in the face of natural challenge with influenza viruses</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">R</forename><surname>Davies</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">A</forename><surname>Grilli</surname></persName>
		</author>
		<idno type="DOI">10.1017/s0950268800030004</idno>
		<idno type="PMID">2703026</idno>
		<idno type="PMCID">PMC2249427</idno>
		<idno type="PII">S0950268800030004</idno>
		<idno type="ark">ark:/67375/6GQ-7VDT5X34-3</idno>
		<idno type="istexId">D60ED649AAC272A085027EB4AF4FAB719B99CCD8</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc2249427?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">Epidemiology and Infection</title>
		<title level="j" type="abbrev">Epidemiol. Infect.</title>
		<idno type="ISSN">0950-2688</idno>
		<idno type="ISSNe">1469-4409</idno>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="issue">02</biblScope>
			<biblScope unit="page" from="325" to="333" />
			<date type="published" when="1989-04" />
			<publisher>Cambridge University Press (CUP)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<monogr>
		<title level="m" type="main">European Committee for Proprietary Medicinal Products. Note for guidance on harmonisation of requirements for influenza vaccines. London: The Europen Agency for the Evaluation of Medicinal Products</title>
		<imprint>
			<date type="published" when="1997" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Immunogenicity of hepatitis B vaccines: implications of immune memory</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Raymond</forename><forename type="middle">S</forename><surname>Koff</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0264-410x(02)00405-x</idno>
		<idno type="PMID">12399197</idno>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<title level="j" type="abbrev">Vaccine</title>
		<idno type="ISSN">0264-410X</idno>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">31-32</biblScope>
			<biblScope unit="page" from="3695" to="3701" />
			<date type="published" when="2002-11" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">A systematic review of intradermal influenza vaccines</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Flora</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Fawziah</forename><surname>Marra</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.vaccine.2011.09.077</idno>
		<idno type="PMID">21968444</idno>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<title level="j" type="abbrev">Vaccine</title>
		<idno type="ISSN">0264-410X</idno>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">48</biblScope>
			<biblScope unit="page" from="8788" to="8801" />
			<date type="published" when="2011-11" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">A Meta-analysis of intradermal versus intramuscular influenza vaccines: Immunogenicity and Adverse Events</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Fawziah</forename><surname>Marra</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Flora</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kathryn</forename><surname>Richardson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Carlo</forename><forename type="middle">A</forename><surname>Marra</surname></persName>
		</author>
		<idno type="DOI">10.1111/irv.12000</idno>
		<idno type="PMID">22974174</idno>
		<idno type="PMCID">PMC5781005</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc5781005?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">Influenza and Other Respiratory Viruses</title>
		<idno type="ISSN">1750-2640</idno>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="584" to="603" />
			<date type="published" when="2012-09-13" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Serum Antibody Responses after Intradermal Vaccination against Influenza</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><forename type="middle">B</forename><surname>Belshe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Frances</forename><forename type="middle">K</forename><surname>Newman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Joan</forename><surname>Cannon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Carol</forename><surname>Duane</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">John</forename><surname>Treanor</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christian</forename><surname>Van Hoecke</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Barbara</forename><forename type="middle">J</forename><surname>Howe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gary</forename><surname>Dubin</surname></persName>
		</author>
		<idno type="DOI">10.1056/nejmoa043555</idno>
		<idno type="PMID">15525713</idno>
	</analytic>
	<monogr>
		<title level="j">New England Journal of Medicine</title>
		<title level="j" type="abbrev">N Engl J Med</title>
		<idno type="ISSN">0028-4793</idno>
		<idno type="ISSNe">1533-4406</idno>
		<imprint>
			<biblScope unit="volume">351</biblScope>
			<biblScope unit="issue">22</biblScope>
			<biblScope unit="page" from="2286" to="2294" />
			<date type="published" when="2004-11-25" />
			<publisher>New England Journal of Medicine (NEJM/MMS)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Antibody responses after dose-sparing intradermal influenza vaccination</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Prasert</forename><surname>Auewarakul</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Uraiwan</forename><surname>Kositanont</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Pornchai</forename><surname>Sornsathapornkul</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paichit</forename><surname>Tothong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Raweewan</forename><surname>Kanyok</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Prasert</forename><surname>Thongcharoen</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.vaccine.2006.08.026</idno>
		<idno type="PMID">17011678</idno>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<title level="j" type="abbrev">Vaccine</title>
		<idno type="ISSN">0264-410X</idno>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="659" to="663" />
			<date type="published" when="2007-01" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Pierre</forename><surname>Van Damme</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Froukje</forename><surname>Oosterhuis-Kafeja</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Marie</forename><surname>Van Der Wielen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yotam</forename><surname>Almagor</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ofer</forename><surname>Sharon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yotam</forename><surname>Levin</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.vaccine.2008.10.077</idno>
		<idno type="PMID">19022318</idno>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<title level="j" type="abbrev">Vaccine</title>
		<idno type="ISSN">0264-410X</idno>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="454" to="459" />
			<date type="published" when="2009-01" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">The immunogenicity of intradermal influenza vaccination in COPD patients</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Benjamas</forename><surname>Chuaychoo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Phunsup</forename><surname>Wongsurakiat</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Arth</forename><surname>Nana</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Uraiwan</forename><surname>Kositanont</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Khun</forename><forename type="middle">Nanta</forename><surname>Maranetra</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.vaccine.2010.04.006</idno>
		<idno type="PMID">20412877</idno>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<title level="j" type="abbrev">Vaccine</title>
		<idno type="ISSN">0264-410X</idno>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">24</biblScope>
			<biblScope unit="page" from="4045" to="4051" />
			<date type="published" when="2010-05" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><forename type="middle">B</forename><surname>Belshe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Frances</forename><forename type="middle">K</forename><surname>Newman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ken</forename><surname>Wilkins</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Irene</forename><forename type="middle">L</forename><surname>Graham</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elizabeth</forename><surname>Babusis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Marian</forename><surname>Ewell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sharon</forename><forename type="middle">E</forename><surname>Frey</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.vaccine.2007.06.066</idno>
		<idno type="PMID">17692438</idno>
		<idno type="PMCID">PMC2148502</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc2148502?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<title level="j" type="abbrev">Vaccine</title>
		<idno type="ISSN">0264-410X</idno>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">37-38</biblScope>
			<biblScope unit="page" from="6755" to="6763" />
			<date type="published" when="2007-09" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jiri</forename><surname>Beran</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Arvydas</forename><surname>Ambrozaitis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alvydas</forename><surname>Laiskonis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Narseta</forename><surname>Mickuviene</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Patrick</forename><surname>Bacart</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yvan</forename><surname>Calozet</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Etienne</forename><surname>Demanet</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stephane</forename><surname>Heijmans</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paul</forename><surname>Van Belle</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Françoise</forename><surname>Weber</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Camille</forename><surname>Salamand</surname></persName>
		</author>
		<idno type="DOI">10.1186/1741-7015-7-13</idno>
		<idno type="PMID">19341446</idno>
		<idno type="PMCID">PMC2676311</idno>
		<ptr type="open-access" target="https://bmcmedicine.biomedcentral.com/track/pdf/10.1186/1741-7015-7-13" />
	</analytic>
	<monogr>
		<title level="j">BMC Medicine</title>
		<title level="j" type="abbrev">BMC Med</title>
		<idno type="ISSNe">1741-7015</idno>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">13</biblScope>
			<date type="published" when="2009-04-02" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18–60 years: Randomized, controlled, Phase III trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><surname>Arnou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Patrick</forename><surname>Eavis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">José-Ramon</forename><surname>De Juanes Pardo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Arvydas</forename><surname>Ambrozaitis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Marie-Pierre</forename><surname>Kazek</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Françoise</forename><surname>Weber</surname></persName>
		</author>
		<idno type="DOI">10.4161/hv.6.4.10961</idno>
		<idno type="PMID">20372053</idno>
	</analytic>
	<monogr>
		<title level="j">Human Vaccines</title>
		<title level="j" type="abbrev">Human Vaccines</title>
		<idno type="ISSN">1554-8600</idno>
		<idno type="ISSNe">1554-8619</idno>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="346" to="354" />
			<date type="published" when="2010-04" />
			<publisher>Informa UK Limited</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Immunogenicity and Safety of Intradermal Influenza Vaccination in Healthy Older Adults</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ru‐chien</forename><surname>Chi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><forename type="middle">T</forename><surname>Rock</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kathleen</forename><forename type="middle">M</forename><surname>Neuzil</surname></persName>
		</author>
		<idno type="DOI">10.1086/652144</idno>
		<idno type="PMID">20377407</idno>
		<idno type="ark">ark:/67375/HXZ-M227S9PZ-G</idno>
		<idno type="istexId">9AE7D3995DCD63FDDBDBFC40FFB7DE11A0084119</idno>
		<ptr type="open-access" target="https://academic.oup.com/cid/article-pdf/50/10/1331/1066125/50-10-1331.pdf" />
	</analytic>
	<monogr>
		<title level="j">Clinical Infectious Diseases</title>
		<title level="j" type="abbrev">CLIN INFECT DIS</title>
		<idno type="ISSN">1058-4838</idno>
		<idno type="ISSNe">1537-6591</idno>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1331" to="1338" />
			<date type="published" when="2010-05-15" />
			<publisher>Oxford University Press (OUP)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Isabel</forename><surname>Leroux-Roels</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eva</forename><surname>Vets</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ralf</forename><surname>Freese</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><surname>Seiberling</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Françoise</forename><surname>Weber</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Camille</forename><surname>Salamand</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Geert</forename><surname>Leroux-Roels</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.vaccine.2008.09.078</idno>
		<idno type="PMID">18930093</idno>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<title level="j" type="abbrev">Vaccine</title>
		<idno type="ISSN">0264-410X</idno>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">51</biblScope>
			<biblScope unit="page" from="6614" to="6619" />
			<date type="published" when="2008-12" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">CDC recommendations expand vaccine indications</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Campos-Outcalt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Fam Pract</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="146" to="154" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Fluzone®Intradermal vaccine: a promising new chance to increase the acceptability of influenza vaccination in adults</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Filippo</forename><surname>Ansaldi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Daniela</forename><surname>De Florentiis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paolo</forename><surname>Durando</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Giancarlo</forename><surname>Icardi</surname></persName>
		</author>
		<idno type="DOI">10.1586/erv.11.154</idno>
		<idno type="PMID">22149703</idno>
	</analytic>
	<monogr>
		<title level="j">Expert Review of Vaccines</title>
		<title level="j" type="abbrev">Expert Review of Vaccines</title>
		<idno type="ISSN">1476-0584</idno>
		<idno type="ISSNe">1744-8395</idno>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="17" to="25" />
			<date type="published" when="2012-01" />
			<publisher>Informa UK Limited</publisher>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
